Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran Cermin Dunia Kedokteran
Jane Cherub
Medical Department, PT. Kalbe Farma Tbk. Jakarta, Indonesia
Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Tinjauan atas Angiotensin Receptor Blocker Generasi Baru Jane Cherub
Cermin Dunia Kedokteran Vol. 47 No. 8 (2020): Oftalmologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v47i8.583

Abstract

Angiotensin receptor blockers (ARB) yang bekerja menghambat reseptor AngII-AT1 secara selektif direkomendasikan sebagai agen antihipertensi lini pertama. Saat ini terdapat 8 varian ARB di pasaran. Selain efek antagonisasinya terhadap AT1, ARB generasi baru memiliki mekanisme tambahan yang dapat menarget hipertensi, penyakit kardiovaskular dan diabetes. ARB generasi baru juga memblokir reseptor endotelin, berfungsi sebagai donor oksida nitrat, menghambat aktivitas neprilysin dan meningkatkan kadar peptida natriuretik, atau merangsang peroxisome proliferator-activated receptor gamma (PPARγ). ARB generasi baru dapat memiliki nilai klinis dan manfaat terapeutik lebih besar daripada hanya melalui penghambatan reseptor AT1. Angiotensin receptor blockers (ARBs) works by selectively blocking AngII-AT1 receptors; it is recommended as a first-line antihypertensive agent. Currently there are 8 variants of ARB in the market. In addition to its AT1 antagonist effect, new generation of ARB can have additional mechanisms on hypertension, cardiovascular disease and diabetes. New generation ARBs also block endothelial receptors, as nitric oxide donors, inhibit neprilysin activity and increase levels of natriuretic peptides, or stimulate peroxisome proliferator-activated gamma receptors (PPARγ). New generation of ARBs can have considerable clinical value and provide greater therapeutic benefits.
Tinjauan atas Angiotensin Receptor Blocker Generasi Baru Jane Cherub
Cermin Dunia Kedokteran Vol 47 No 8 (2020): Oftalmologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v47i8.583

Abstract

Angiotensin receptor blockers (ARB) yang bekerja menghambat reseptor AngII-AT1 secara selektif direkomendasikan sebagai agen antihipertensi lini pertama. Saat ini terdapat 8 varian ARB di pasaran. Selain efek antagonisasinya terhadap AT1, ARB generasi baru memiliki mekanisme tambahan yang dapat menarget hipertensi, penyakit kardiovaskular dan diabetes. ARB generasi baru juga memblokir reseptor endotelin, berfungsi sebagai donor oksida nitrat, menghambat aktivitas neprilysin dan meningkatkan kadar peptida natriuretik, atau merangsang peroxisome proliferator-activated receptor gamma (PPARγ). ARB generasi baru dapat memiliki nilai klinis dan manfaat terapeutik lebih besar daripada hanya melalui penghambatan reseptor AT1. Angiotensin receptor blockers (ARBs) works by selectively blocking AngII-AT1 receptors; it is recommended as a first-line antihypertensive agent. Currently there are 8 variants of ARB in the market. In addition to its AT1 antagonist effect, new generation of ARB can have additional mechanisms on hypertension, cardiovascular disease and diabetes. New generation ARBs also block endothelial receptors, as nitric oxide donors, inhibit neprilysin activity and increase levels of natriuretic peptides, or stimulate peroxisome proliferator-activated gamma receptors (PPARγ). New generation of ARBs can have considerable clinical value and provide greater therapeutic benefits.
Co-Authors